Supply Price and Royalty Sample Clauses

Supply Price and Royalty. (a) In consideration of the manufacture of Bulk Licensed Compound and the grant of licenses hereunder, GENE will pay to Biosearch a supply price (the "Supply Price") and a royalty (the "Royalty") as described in the table set forth below. The Supply Price will be ***** of Bulk Licensed Compound. Except as otherwise set forth in this Section 8.2, the Royalty on GENE's Net Sales will be equal to the ***** indicated in the table set forth below and the *****. -------------------------------------------------------------------------------------------------------------------- Total Payment Due -------------------------------------------------------------------------------------------------------------------- Non-Exclusive; Non-Exclusive; Exclusive TBP can be determined TBP cannot be determined -------------------------------------------------------------------------------------------------------------------- ***** Greater of ***** of Net Greater of ***** of Net Sales or ***** of Net Sales, but not -------------------------------------------------------------------------------------------------------------------- ---------- *Confidential Treatment has been requested for the marked portions. ----------------------------------------------------------------------------------------------------------------------------- from Sales or ***** per gram ***** per gram of Bulk Licensed more than ***** per gram Effective Date of Bulk Licensed Compound, but reduced to TBP if of Bulk Licensed Compound TBP is less than ***** per gram Compound ---------------------------------------------------------------------------------------------------------------------------- ***** Greater of ***** of Net Greater of ***** of Net Sale or ***** of Net Sales, but not Sales or ***** per gram ***** per gram, but reduced more than ***** per gram from of Bulk Licensed to TBP if TBP is less than ***** of Bulk Licensed Effective Compound per gram Compound Date ----------------------------------------------------------------------------------------------------------------------------- As used above, the following terms shall have the following meanings:
Sample 1
AutoNDA by SimpleDocs
Supply Price and Royalty. 28.01 ARS shall supply the Product to Recordati at the relevant Supply Price set out in Annex 6.
Sample 1
Supply Price and Royalty. (a) In consideration of the manufacture of Bulk Licensed Compound and the grant of licenses hereunder, GENE will pay to Biosearch a supply price (the "Supply Price") and a royalty (the "Royalty") as described in the table set forth below. The Supply Price will be*****the Royalty on GENE's Net Sales will be*****. As used above, the following terms shall have the following meanings: ***** Notwithstanding the foregoing, the Parties agree to the desirability of maintaining a competitive price and competitive supply arrangements for Licensed Products in the face of increased competition. In the event that the adjustments to the total payments described in the table above are not able or are inadequate to meet GENE's needs to modify GENE's costs for Licensed Products as reasonably determined by GENE, the Parties hereby agree to negotiate in good faith to establish other mechanisms as may be deemed necessary to maintain competitiveness in the marketplace.
Sample 1
Supply Price and Royalty 
Sample 1Sample 2Sample 3See All (6)

Related to Supply Price and Royalty

  • Supply Price The price payable by SAVIENT to NOF for the Activated PEG manufactured and supplied by NOF pursuant to SAVIENT’s Firm Orders (“Supply Price”) shall be as set out in Exhibit C, and the price for each order shall be calculated based on SAVIENT’s total Forecast for the Year in which the order is placed regardless of whether NOF shall complete delivery in the Year in which it is ordered. By way of example, if SAVIENT’s Forecast for a particular Year is for [**] kg of the Activated PEG, then orders placed during that Year will be charged at US$[**]/Kg. If at the end of any Year actual orders purchased by SAVIENT do not fall within the applicable quantity range of the original Forecast, then the Price for the Activated PEG purchased during that Year shall be adjusted to reflect that actual volume of Activated PEG purchased by SAVIENT, provided, however, if the actual amount purchased by SAVIENT is less than Forecasted due to [**], then the Price for the Activated PEG purchased by Savient shall be based on [**]. Upon adjustment, if necessary, either SAVIENT shall pay to NOF or NOF shall credit to SAVIENT, as applicable, the balance based on the said adjustment. Any amounts owing by SAVIENT to NOF pursuant to this provision shall be remitted within [**] days of the SAVIENT’s receipt of a reconciliation statement which sets forth in specific detail the amounts purchased by SAVIENT during the Year in question; any credits owing by NOF to SAVIENT shall be applied to [**]. Provided, however, that SAVIENT shall pay to NOF only such amount as corresponds with the amount of Activated PEG which is actually delivered to SAVIENT or SAVIENT’S designee pursuant to the terms of this Agreement.

  • Production Royalty The amount of the Royalty shall be determined at the end of each month after the Effective Date. The Royalty shall be determined monthly on the basis such that payments will be determined as of and paid within thirty (30) days after the last day of each month during which Lessee produces any Geothermal Resources. The Royalty rates shall be determined as follows:

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Royalty Fee The Licensee agrees to pay AmericaTowne a monthly fee equal to 7.5% of its Gross Retail Sales (the "Royalty Fee").

  • Royalty Payment For all leased substances that are sold during a particular month, Lessee shall pay royalties to Lessor on or before the end of the next succeeding month. Royalty payments shall be accompanied by a verified statement, in a form approved by Lessor, stating the amount of leased substances sold, the gross proceeds accruing to Lessee, and any other information reasonably required by Lessor to verify production and disposition of the leased substances or leased substances products. Delinquent royalties may be subject to late fees and penalties in accordance with Lessor’s Rules.

  • Royalty Rates On a Licensed Product-by-Licensed Product and country-by-country basis, during the Royalty Term, Imugene shall pay to Precision a royalty equal to the percentages of aggregate annual global Net Sales of such Licensed Product, as set forth below (the “Royalty”), calculated by multiplying the applicable royalty rate percentage by the corresponding portion of aggregate global Net Sales for such Licensed Product in such Calendar Year. For purposes of determining whether the Net Sales thresholds in the table below have been achieved for a Licensed Product, all Net Sales of such Licensed Product shall be aggregated globally for all sales made by Imugene or any of its Affiliates or its or their Sublicensees of such Licensed Product, in any and all preparations, formulations, dosages, packaging or methods of administration thereof. Annual Net Sales of the Applicable Licensed Product Royalty Rate Aggregate annual global Net Sales of an Existing Product less than [***] [***] Aggregate annual global Net Sales of an Existing Product equal to or greater than [***] but less than [***] [***] Aggregate annual global Net Sales of an Existing Product equal to or greater than [***] [***] Aggregate annual global Net Sales of an Additional Product less than [***] [***] Aggregate annual global Net Sales of an Additional Product equal to or greater than [***] but less than [***] [***] Aggregate annual global Net Sales of an Additional Product equal to or greater than [***] [***]

  • Royalties 1. Royalties arising in a Contracting State and paid to a resident of the other Contracting State may be taxed in that other State.

Time is Money Join Law Insider Premium to draft better contracts faster.